Your AI-Trained Oncology Knowledge Connection!
Panelists discuss how adjuvant durvalumab after chemoradiotherapy (PACIFIC trial) established the standard of care for locally advanced non–small cell lung cancer, while the DUART trial showed potential benefits even in frail patients treated with radiation alone, the COAST trial demonstrated improved outcomes by adding trebananib to durvalumab, and the ADRIATIC trial revealed significant survival benefits from adjuvant durvalumab in limited-stage small cell lung cancer.
Panelists discuss how the LAURA trial demonstrated dramatic progression-free survival improvements with adjuvant osimertinib for EGFR-mutated stage III lung cancer, while the SINDAS, NORTHSTAR, and LONESTAR trials explore whether upfront local consolidative radiation therapy to oligometastatic sites can improve outcomes in both EGFR-mutated and nonmutated metastatic disease.
Panelists discuss how radiation oncologists can increase pulmonologist awareness about radiation therapy through multidisciplinary collaboration, educating colleagues about modern treatment capabilities, engaging them in fiducial placement and toxicity management, and positioning radiation oncology as both an upstream and downstream service that can help solve pulmonologists’ clinical challenges.
Panelists discuss how the future of stage III non–small cell lung cancer treatment may shift from concurrent chemoradiotherapy toward sequential approaches with upfront systemic intensification (chemotherapy plus immunotherapy) followed by ablative radiation, mirroring successful surgical paradigms while acknowledging that concurrent therapy remains the current standard until proven otherwise.
Panelists discuss how the future of brain control in limited-stage small cell lung cancer may trend toward MRI surveillance rather than prophylactic cranial irradiation (PCI) given its toxicity and the availability of effective salvage stereotactic radiosurgery, though survival benefits from historical PCI trials and shared decision-making still support offering hippocampal-avoidant PCI with memantine until definitive data from trials like MAVERICK emerge.
Panelists discuss how the decision to offer local consolidative therapy in oligometastatic non–small cell lung cancer depends on multiple factors including PET scan activity at 6 months, the feasibility of rendering patients with no evidence of disease, multidisciplinary collaboration, and the emerging need for a “third box” treatment category beyond curative and palliative intent that addresses preemptive strikes against limited progressive sites to prolong survival.
